Cargando…

Long-Term Hematologic Improvement in a Patient With Cytopenic Myelofibrosis Treated With Pacritinib

Detalles Bibliográficos
Autores principales:	Yacoub, Abdulraheem, Mesa, Ruben A., Oh, Stephen T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2023
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9929105/ https://www.ncbi.nlm.nih.gov/pubmed/36634298 http://dx.doi.org/10.1200/PO.22.00523

Ejemplares similares

Long-term treatment with pacritinib on a compassionate use basis in patients with advanced myelofibrosis
por: Harrison, Claire, et al.
Publicado: (2023)

Risk‐adjusted safety analysis of the oral JAK2/IRAK1 inhibitor pacritinib in patients with myelofibrosis
por: Pemmaraju, Naveen, et al.
Publicado: (2022)

Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia
por: Verstovsek, Srdan, et al.
Publicado: (2021)

The odyssey of pacritinib in myelofibrosis
por: Venugopal, Sangeetha, et al.
Publicado: (2022)

Is Treatment for Cytopenic Myelofibrosis Still an Unmet Clinical Need?
por: Caduc, Madeline J., et al.
Publicado: (2023)

P1068: RISK-ADJUSTED SAFETY ANALYSIS OF PACRITINIB IN PATIENTS WITH MYELOFIBROSIS
por: Vannucchi, A., et al.
Publicado: (2022)

Emerging treatment options for myelofibrosis: focus on pacritinib
por: Chow, Vivian, et al.
Publicado: (2016)

Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis
por: Oh, Stephen T., et al.
Publicado: (2023)

Differential prognostic impact of cytopenic phenotype in prefibrotic vs overt primary myelofibrosis
por: Coltro, Giacomo, et al.
Publicado: (2022)

P1069: RETROSPECTIVE COMPARISON OF PATIENT OUTCOMES ON PACRITINIB VERSUS RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS AND THROMBOCYTOPENIA
por: Harrison, C., et al.
Publicado: (2022)

P1057: INDIRECT TREATMENT COMPARISONS OF MOMELOTINIB VS PACRITINIB SAFETY AND ANEMIA OUTCOMES IN PATIENTS WITH MYELOFIBROSIS
por: Masarova, Lucia, et al.
Publicado: (2023)

Nonclonal chromosomal alterations and poor survival in cytopenic patients without hematological malignancies
por: Imataki, Osamu, et al.
Publicado: (2019)

P1037: CONSISTENCY OF PACRITINIB FOR SPLEEN AND SYMPTOM REDUCTION IN PATIENTS WITH MYELOFIBROSIS REGARDLESS OF CYTOPENIAS
por: Gagelmann, Nico, et al.
Publicado: (2023)

Primary Myelofibrosis Presenting as Extramedullary Hematopoiesis in a Transplanted Liver Graft: Case Report and Review of the Literature
por: Mohyuddin, Ghulam Rehman, et al.
Publicado: (2016)

Profile of pacritinib and its potential in the treatment of hematologic disorders
por: Hatzimichael, Eleftheria, et al.
Publicado: (2014)

Targeting hedgehog signaling in myelofibrosis and other hematologic malignancies
por: Tibes, Raoul, et al.
Publicado: (2014)

Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor
por: Singer, Jack W, et al.
Publicado: (2016)

P1059: COMPARATIVE EFFICACY OF FEDRATINIB AND PACRITINIB FOR THE TREATMENT OF MYELOFIBROSIS IN PATIENTS WITH LOW PLATELET COUNTS: A SIMULATED TREATMENT COMPARISON STUDY
por: Tremblay, G., et al.
Publicado: (2022)

Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses
por: Verstovsek, Srdan, et al.
Publicado: (2017)

Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies
por: Verstovsek, Srdan, et al.
Publicado: (2016)

P987: IRAK1 AND JAK2 DUAL INHIBITION WITH PACRITINIB PREVENTS MYELOFIBROSIS-LIKE PHENOTYPE IN AN INFLAMMATION-DRIVEN MURINE MODEL
por: Zamora, Ernesto José Cuenca, et al.
Publicado: (2023)

Ruxolitinib improves symptoms and quality of life in a patient with systemic mastocytosis
por: Yacoub, Abdulraheem, et al.
Publicado: (2016)

Ruxolitinib: Long-Term Management of Patients with Myelofibrosis and Future Directions in the Treatment of Myeloproliferative Neoplasms
por: Yacoub, A., et al.
Publicado: (2014)

The evolving treatment paradigm in myelofibrosis
por: Mesa, Ruben A.
Publicado: (2013)

Utility of targeted gene sequencing to differentiate myeloid malignancies from other cytopenic conditions
por: DeZern, Amy E., et al.
Publicado: (2023)

Targeted Sequencing Informs the Evaluation of Normal Karyotype Cytopenic Patients for Low-Grade Myelodysplastic Syndrome
por: Duncavage, Eric J., et al.
Publicado: (2016)

P1030: SPLEEN VOLUME REDUCTION PREDICTS SURVIVAL IN MYELOFIBROSIS PATIENTS ON PACRITINIB BUT NOT BEST AVAILABLE THERAPY: PERSIST-2 LANDMARK OVERALL SURVIVAL ANALYSIS
por: Bewersdorf, Jan, et al.
Publicado: (2023)

Myelofibrosis-Related Arthritis Successfully Treated with Hydroxyurea
por: Guillot, Xavier, et al.
Publicado: (2014)

Pacritinib abrogates the lupus phenotype in ABIN1[D485N] mice
por: Petrova, Tsvetana, et al.
Publicado: (2023)

The role of fedratinib for the treatment of patients with primary or secondary myelofibrosis
por: Palmer, Jeanne, et al.
Publicado: (2020)

Pulmonary cryptococcosis in a ruxolitinib-treated patient with primary myelofibrosis
por: Hirano, Anna, et al.
Publicado: (2017)

Management of myelofibrosis after ruxolitinib failure
por: Harrison, Claire N, et al.
Publicado: (2020)

Profile of pomalidomide and its potential in the treatment of myelofibrosis
por: Gowin, Krisstina L, et al.
Publicado: (2015)

Hematological manifestations of human T lymphotropic virus type 1 infection: a possible association with autoimmune myelofibrosis
por: Ciminelli, Ana, et al.
Publicado: (2016)

Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing
por: Mesa, Ruben A, et al.
Publicado: (2013)

Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials
por: Verstovsek, Srdan, et al.
Publicado: (2023)

S249: SELECTIVE JAK2/IRAK1/ACVR1 INHIBITOR PACRITINIB BEFORE REDUCED-INTENSITY CONDITIONING ALLOGENEIC STEM CELL TRANSPLANTATION IN MYELOFIBROSIS: FINAL ANALYSIS OF THE PHASE II HOVON-134 TRIAL
por: Van Dijck, Ruben, et al.
Publicado: (2023)

Pitfalls in Interventional Pain Medicine: Hyponatremia after DDAVP for a Patient with Von Willebrand Disease Undergoing an Epidural Steroid Injection
por: Khan, Talal W., et al.
Publicado: (2017)

Defining disease modification in myelofibrosis in the era of targeted therapy
por: Pemmaraju, Naveen, et al.
Publicado: (2022)

Long-term Effects of the Janus Kinase 1/2 Inhibitor Ruxolitinib on Pulmonary Hypertension and the Cardiac Function in a Patient with Myelofibrosis
por: Miyawaki, Hiroshi, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_lkmf6463ls6fcn8j6md4rkl6gm